Context Therapeutics (NASDAQ:CNTX) Rating Lowered to “Strong Sell” at Wall Street Zen

Posted by Stanley Muller on Jul 22nd, 2026

Context Therapeutics (NASDAQ:CNTX – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Monday.

A number of other equities analysts have also issued reports on CNTX. Guggenheim reaffirmed a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a research note on Tuesday, March 24th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research note on Tuesday, March 24th. Maxim Group cut their price objective on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Piper Sandler raised their target price on Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.17.

Read Our Latest Report on Context Therapeutics

Context Therapeutics Trading Up 2.3%

CNTX stock opened at $0.63 on Monday. The firm’s 50-day moving average is $1.35 and its two-hundred day moving average is $2.00. The company has a market capitalization of $57.88 million, a price-to-earnings ratio of -1.50 and a beta of 1.75. Context Therapeutics has a 52 week low of $0.55 and a 52 week high of $3.62.

Context Therapeutics (NASDAQ:CNTX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03. On average, equities research analysts predict that Context Therapeutics will post -0.39 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CNTX. Virtu Financial LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter valued at $43,000. Sanctuary Advisors LLC acquired a new position in shares of Context Therapeutics in the 1st quarter worth $51,000. Quadrature Capital Ltd acquired a new stake in shares of Context Therapeutics during the fourth quarter worth $68,000. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics during the third quarter worth $100,000. Finally, XTX Topco Ltd lifted its holdings in shares of Context Therapeutics by 858.8% during the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after purchasing an additional 91,008 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

(Get Free Report)

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.